Who Should Pay for Ozempic Is the Next Big Workplace Fight
Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.
Here's how much Ozempic and similar drugs have soared in popularity since 2018
The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and ...
Houston-area company may be developing next hot weight-loss drug
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
La pilule antidiabétique de Novo Nordisk réduit le risque de complications cardiovasculaires
Selon un communiqué de presse, la pilule antidiabétique Rybelsus de la société pharmaceutique danoise Novo Nordisk réduit le ...
Un enfant atteint d’une maladie rare obtient un sursis de trois mois
Xavier Renaud, un garçon de Bellechasse aux prises avec une déficience génétique extrêmement rare, aura droit à encore trois mois du traitement qui l’autorise à espérer une vie normale. La victoire ...
Novo Nordisk presents results from STRIDE study on Ozempic
Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...
Futurism2d
Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.
Novo says Ozempic succeeded in late-stage trial for peripheral artery disease
Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...
Novo Nordisk A/S présente les résultats complets de l'étude STRIDE
Novo Nordisk a présenté les résultats complets de STRIDE, un essai de phase 3b sur les résultats de la maladie artérielle ...
Cheaper and More Effective: New MIT Breakthrough Could Improve Popular Weight Loss Drugs Such As Ozempic
MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
Trends-Tendances7d
Novo Nordisk : le marché croit de moins en moins à son prochain médicament “miracle”
Après une hausse flamboyante, Novo Nordisk rechute de manière tout aussi spectaculaire en bourse. Que se passe-t-il ?.